

Amendments to the Claims

The following listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) An adamantan ~~[Adamantan]~~ ammonium salt[s] of 5-methoxy-2-[[~~(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl~~]sulfinyl]-1*H*-benzimidazole (omeprazole) ~~[and of]~~ or (S)-5-methoxy-2-[[~~(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl~~]sulfinyl]-1*H*-benzimidazole (esomeprazole).
2. (Currently amended) The adamantan ammonium salt according to claim 1, wherein the salt is a 1-adamantan ammonium salt of omeprazole.
3. (Currently amended) The adamantan ammonium salt according to claim 1, wherein the salt is a 1-adamantan ammonium salt of esomeprazole.
4. (Currently amended) The adamantan ammonium salt according to ~~[any of claims 1,]~~ claim 1, wherein the salt is a 2-adamantan ammonium salt of omeprazole.
5. (Currently amended) The adamantan ammonium salt according to claim 1, wherein the salt is a 2-adamantan ammonium salt of esomeprazole.
6. (Currently amended) The adamantan ammonium salt[s] according to ~~[any of claims 1 to 5 characterized in that the compound]~~ claim 1, wherein the salt is crystalline.
7. (Currently amended) A process for the preparation of ~~[an]~~ the adamantan ammonium salt ~~[of omeprazole and of esomeprazole, according to any of claims 1 to 6, which]~~ according to claim 1, wherein the process comprises the ~~[following]~~ steps of:
 - a) dissolving omeprazole or esomeprazole in an organic solvent;
 - b) adding an adamantan amine and precipitating the desired salt; and
 - c) isolating and drying ~~[of]~~ the obtained salt ~~[of omeprazole or esomeprazole]~~.

8. (Currently amended) The process according to claim 7, wherein the organic solvent is selected from the group consisting of acetonitrile, ethyl acetate, *tert*-butyl methyl ether, ~~[and]~~ methanol, ~~[or a]~~ and mixtures thereof.

9. (Currently amended) The process according to claim 7, wherein the organic solvent is selected from the group consisting of acetonitrile, ethyl acetate, ~~[and]~~ methanol, ~~[or]~~ and mixtures thereof.

10. (Currently amended) The process according to ~~[any of claims 7 to 9]~~ claim 7, wherein the obtained salt is an adamantan ammonium salt of omeprazole ~~[is obtained]~~.

11. (Currently amended) The process according to ~~[any of claims 7 to 9]~~ claim 7, wherein the obtained salt is an adamantan ammonium salt of esomeprazole ~~[is obtained]~~.

12. (Currently amended) A pharmaceutical composition comprising the adamantan ammonium salt of omeprazole or esomeprazole according to any one of claims 1 to 6 as active ingredient ~~[s in association with]~~ and one or more pharmaceutically acceptable excipients ~~[and optionally other therapeutic ingredients]~~.

13. (Canceled)

14. (Currently amended) A method for treatment of a gastric acid related condition, which method ~~[comprised]~~ comprises administering ~~[to a subject suffering from said condition]~~ a therapeutically effective amount of the adamantan ammonium salt of omeprazole or esomeprazole according to any one of claims 1 to 6 to a patient in need thereof.

15. (New) The pharmaceutical composition according to claim 12, further comprising one or more additional therapeutic ingredients.